Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):581-6. doi: 10.1016/j.ijrobp.2011.07.035. Epub 2011 Dec 2.
The goal of this study was to evaluate dosimetric parameters, acute toxicity, pathologic response, and local control in patients treated with preoperative intensity-modulated radiation therapy (IMRT) and concurrent chemotherapy for localized gastric adenocarcinoma.
Between November 2007 and April 2010, 25 patients with localized gastric adenocarcinoma were treated with induction chemotherapy, followed by preoperative IMRT and concurrent chemotherapy and, finally, surgical resection. The median radiation therapy dose was 45 Gy. Concurrent chemotherapy was 5-fluorouracil and oxaliplatin in 18 patients, capecitabine in 3, and other regimens in 4. Subsequently, resection was performed with total gastrectomy in 13 patients, subtotal gastrectomy in 7, and other surgeries in 5.
Target coverage, expressed as the ratio of the minimum dose received by 99% of the planning target volume to the prescribed dose, was a median of 0.97 (range, 0.92-1.01). The median V(30) (percentage of volume receiving at least 30 Gy) for the liver was 26%; the median V(20) (percentage of volume receiving at least 20 Gy) for the right and left kidneys was 14% and 24%, respectively; and the median V(40) (percentage of volume receiving at least 40 Gy) for the heart was 18%. Grade 3 acute toxicity developed in 14 patients (56%), including dehydration in 10, nausea in 8, and anorexia in 5. Grade 4 acute toxicity did not develop in any patient. There were no significant differences in the rates of acute toxicity, hospitalization, or feeding tube use in comparison to those in a group of 50 patients treated with preoperative three-dimensional conformal radiation therapy with concurrent chemotherapy. R0 resection was obtained in 20 patients (80%), and pathologic complete response occurred in 5 (20%).
Preoperative IMRT for gastric adenocarcinoma was well tolerated, accomplished excellent target coverage and normal structure sparing, and led to appropriate pathologic outcomes.
本研究旨在评估局部胃腺癌患者术前接受调强放疗(IMRT)和同期化疗的剂量学参数、急性毒性、病理反应和局部控制情况。
2007 年 11 月至 2010 年 4 月,25 例局部胃腺癌患者接受诱导化疗,随后行术前 IMRT 和同期化疗,最后行手术切除。中位放疗剂量为 45Gy。同期化疗方案中,18 例患者接受氟尿嘧啶和奥沙利铂化疗,3 例患者接受卡培他滨化疗,4 例患者接受其他方案化疗。随后,13 例患者行全胃切除术,7 例行胃大部切除术,5 例行其他手术。
靶区覆盖率(即计划靶区体积接受 99%处方剂量的最小剂量与处方剂量的比值)的中位数为 0.97(范围,0.92-1.01)。肝脏的中位 V30(接受至少 30Gy 剂量的体积百分比)为 26%;右肾和左肾的中位 V20(接受至少 20Gy 剂量的体积百分比)分别为 14%和 24%;心脏的中位 V40(接受至少 40Gy 剂量的体积百分比)为 18%。14 例(56%)患者出现 3 级急性毒性,包括 10 例脱水,8 例恶心,5 例厌食。无 4 级急性毒性。与 50 例接受术前三维适形放疗同期化疗的患者相比,两组患者的急性毒性、住院和置管率无显著差异。20 例(80%)患者获得 R0 切除,5 例(20%)患者发生病理完全缓解。
术前 IMRT 治疗胃腺癌患者耐受性良好,可实现优异的靶区覆盖和正常结构保护,并获得适当的病理结果。